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E-mail address: Magnus.Back@ki.se (M. Bäck).Valvular interstitial cells (VICs) are of mesenchymal origin and may differentiate into immune-like
cells. This phenotypic plasticity is a key feature of aortic valve stenosis, but the role of epigenetic
mechanisms has not previously been explored. Here we compared normal and calciﬁed human
aortic valve tissue. Calciﬁed tissue exhibited decreased DNA-methylation in the promoter of the
gene encoding the proinﬂammatory enzyme 5-lipoxygenase (5-LO), accompanied by increased
5-LO mRNA levels. Treatment of cultured VICs with the DNA methyltransferase inhibitor:
5-Aza-2’-deoxycytidine increased 5-LO mRNA levels and leukotriene production. These ﬁndings
provide a ﬁrst piece of evidence for epigenetic modiﬁcations of VICs in valvular heart disease.
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Valvular interstitial cells (VICs), the dominating cell type in aor-
tic valves, are responsible for the maintenance of valve integrity.
Phenotypic transdifferentiation of VICs, determined as an altered
expression proﬁle of cytoskeletal and surface proteins, reﬂects an
age-related adaptation mechanism of the valvular structure, which
is associated with a physiological maturation process [1]. VICs
hence represent a highly plastic cell population with dynamic
phenotypic features, including different subpopulations that may
exhibit osteogenic, adipogenic, chondrogenic, and myoﬁbrogenic
characteristics [2].
Under pathological conditions, a subset of interstitial cells may
for example undergo phenotypic transdifferentiation toward bone-
producing osteoblast-like cells with expression of osteogenic
mediators such as osteocalcin, bone sialoprotein, and osteonectin,
which participate in the active calciﬁcation associated with aortic
stenosis [3,4]. However, the underlying phenomenon involved in
this phenotypic modiﬁcation of VICs remains to be established.
The involvement of epigenetics led to a paradigm shift in the
current understanding of atherosclerosis [5]. Likewise, in tumor-
genesis, epigenetic modiﬁcations through DNA hypomethylationchemical Societies. Published by E
cular Medicine, CMM L8:03,
eden.have been associated with the activation of certain oncogenes
[6]. However, the role of epigenetics in aortic stenosis may have
been hitherto overlooked. Dynamic changes in DNA methylation
pattern are tightly associated with transcriptional silencing or acti-
vation of certain genes. The dynamic status of DNA methylation is
potentially reversible either by physiological, and pathophysiolog-
ical conditions, or can be induced pharmacologically and detected
quantitatively [6,7].
One example of a possibly epigenetically regulated pathway is
the formation of leukotrienes, a group of arachidonate-derived lipid
mediators with proinﬂammatory properties [8,9], which have been
implicated in several cardiovascular pathologies [10,11] such as
aortic stenosis [12]. We recently demonstrated expression of the
leukotriene-synthesizing enzyme, 5-lipoxygenase (5-LO) in aortic
stenosis [12]. Although, according to current paradigms, lipoxygen-
ases are considered almost exclusively expressed in a variety of
myeloid cells [10,11], our morphological analysis of stenotic aortic
valves indicated that also VICs express 5-LO [12]. These results sug-
gested that structural valvular cells can trigger inﬂammation with-
out the involvement of immune cells [12]. Although these ﬁndings
were in line with earlier studies in vascular smooth muscle cells
[13], a mesenchymal cell type sharing many similarities with VICs,
the underlying mechanisms of 5-LO induction in non-myeloid cells
has not previously been explored.
Interestingly, 5-LO expression is regulated by promoter methyl-
ation [8,9]. Genetic variations have been reported with a decreasedlsevier B.V. All rights reserved.
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Fig. 1. Extent of methylation of 5-LO promoter region (A; n = 8 preparations from 4
patients. The data are presented as a fold change compared to the methylation level
in non-calciﬁed tissue) and 5-LO mRNA levels (B; n = 12 preparations from 6
patients) in non-calciﬁed (thickened) and calciﬁed parts of human stenotic aortic
valves. ⁄P < 0.05; compared with non-calciﬁed part.
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susceptibility to methylation [14]. These polymorphisms were
associated with increased measures of subclinical atherosclerosis
[15], hence supporting the notion of an important epigenetic regu-
lation of 5-LO activity in cardiovascular pathology. However, there
is no previous work on epigenetic regulation of calciﬁed aortic
valve stenosis. Based on the above studies, the hypothesis of the
present study was that epigenetic modiﬁcation could lead to a
transformation of VICs into leukotriene-producing immune-like
cells with a potential to aggravate pathological processes.
2. Materials and methods
2.1. Study population
Human aortic valves were obtained from 17 patients undergo-
ing aortic valve replacement surgery for aortic valve disease. The
study has been approved by the local Ethics Committee (Reference
2008/630–32), and all patients gave informed consent. Only pa-
tients with a normal preoperative coronary angiogram and without
history of rheumatic heart disease were included in the study.
Valves were macroscopically dissected into normal, thickened
and calciﬁed parts as previously described [12].
2.2. Valvular interstitial cell isolation
Aortic valves from 7 patients were used for isolation of VICs, as
previously described [12]. Outgrowth of VICs was evaluated and
culture medium was changed 3 times per week. On average,
2–3 weeks of incubation were needed to obtain conﬂuent out-
growth of the VICs. Cells were used for experiments between pas-
sages 2 and 4.
2.3. Double immunoﬂuorescence staining
Human VICs derived from stenotic aortic valves were cultured in
LabTek slide chambers followed by ﬁxation and permeabilization
with acetone-methanol, and further subjected to double immuno-
ﬂuorescence staining using polyclonal rabbit anti-human 5-LO (Life
Science Bioscience) and monoclonal mouse anti-human vimentin
as primary antibodies. Isotype-speciﬁc either Texas Red or Alexa
Fluor 488-conjugated secondary antibodies (Abcam) were used;
nuclei were counterstained with 4‘, 6-diamino-2-phenylindol
(DAPI, Vector). Images were captured with confocal microscope
Leica DMI.
2.4. DNA hypomethylation by 5-aza-20-deoxycytidine (AdC)
Cellswere seeded into 6-well plates and incubated for 96 h in the
absence or presence of the hypomethylating agent, 5-aza-20-deoxy-
cytidine (AdC; Sigma) at different concentrations (100 nM–10 lM).
The cell culture medium and AdC were replaced every 24 h.
2.5. mRNA and DNA extraction
The cells were harvested for RNA and DNA isolation using the
AllPrep RNA&DNA kit (Qiagen) according to the manufacturer’s
instructions. DNA and mRNA extraction from non-calciﬁed (thick-
ened) and calciﬁed parts of valvular tissue was performed using
DNeasy and RNeasy kits (Qiagen), respectively.
2.6. cDNA synthesis and TaqMan real-time PCR
First-strand cDNA was synthesized from 0.5 lg RNA (Super-
script II, Invitrogen, Carlsbad, CA) with random hexamers accord-
ing to the manufacturer‘s instructions. Quantitative TaqMan PCRwas performed on a 7900HT Fast Real-Time PCR system (Applied
Biosystems) with primer/probe pairs that were obtained using
Assay-on-demand™ from Applied Biosystems (Cyclophilin A; PPIA:
Hs99999904_m1; 5-Lipoxygenase; 5-LO: Hs00167536_m1). The
reactions contained 5 ll cDNA that was diluted to 1.5 ng/ll and
5 ll TaqMan™ Fast Universal PCR Master Mix (Applied Biosystems,
Foster City, USA). Results for 5-LO were normalized to expression
levels of PPIA, as previously described [12].
2.7. Analysis of the DNA methylation status of the 5-LO promoter
region
Genomic DNA extracted from VICs and valve tissue was further
analyzed using the DNA Methylation Enzyme Kit (SA Biosciences),
essentially as previously described [16]. In summary, DNA is di-
gested with methylation sensitive- and methylation-dependent
restriction enzymes selectively digesting the unmethylated and
the methylated DNA, respectively. The change in Ct between the
treatments using the double digest and the mock digest serves as
the average analytical window. The resistant fraction after each
treatment is assessed by SYBR green-based Methyl-Proﬁler™ qPCR
Primer Assay for Human ALOX5 (CpG Island: 13671; Related
Refseq: NM_000698 (ALOX5); TSS Position: 45189635; TSS Orien-
tation: Forward; SA Biosciences).
2.8. Elisa
Concentrations of LTB4 in supernatants from VICs were deter-
mined by ELISA (Cayman Chemical), as previously described [17].
2.9. Data analysis
All results are expressed as mean ± S.E. Statistically signiﬁcant
differences were determined by either a Mann–Whitney rank
sum test (for pair-wise comparisons) or a one way analysis of
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Fig. 2. Effects of treatment with 5-aza-2‘-deoxycytidine (AdC) in valvular interstitial cells (VICs) derived from human aortic valves (n = 4–7) on the degree of methylation of
the 5-LO promoter DNA (A), 5-LO mRNA levels (B) and LTB4 concentrations in VIC supernatants (C). P-value indicates results of ANOVA. Panel D shows representative example
for the colocalization of 5-LO protein with vimentin in primary isolated VICs from stenotic aortic valves tissue, using double immunoﬂuorescence staining.
E. Nagy, M. Bäck / FEBS Letters 586 (2012) 1325–1329 1327variance (ANOVA), (for multiple comparisons) using SigmaStat
software. Correlation between qPCR for 5-LO and the extent of
methylated 5-LO promoter in aortic valves was established by
Spearman correlation. A P-value of less than 0.05 was considered
signiﬁcant.
3. Results
3.1. The DNA methylation status of the 5-LO promoter and its
transcriptional proﬁle in surgically explanted human aortic valve tissue
Methylation within the 5-LO promoter region was assessed
with the use of restriction enzymes sensitive or resistant to CpG
methylation at the cutting sites, followed by qPCR to quantify
DNA methylation at their recognition sites (here termed methyl-
ated DNA = densely methylated fraction). With this assay calciﬁed
human aortic valve tissue exhibited a signiﬁcantly lower degree of
methylated DNA (0.38 ± 0.28%) compared with non-calciﬁed
valvular tissue (2.1 ± 0.55%; p = 0.028); data are expressed as a fold
change compared to the methylation level in non-calciﬁed tissue
(Fig. 1A). This was accompanied by an increase in 5-LO mRNA lev-
els 2.1 ± 0.41-fold (p = 0.003; Fig. 1B), although a part of thisincrease may be accounted for by increased numbers of leukocytes
in calciﬁed tissue [12]. For this reason we further examined 5-LO
expression in puriﬁed cultures of VICs. There was a signiﬁcant
and inverse correlation between 5-LO promoter methylation and
5-LO mRNA levels in aortic valves (r = 0.5, p = 0.04).
3.2. DNA methylation status of the 5-LO promoter and its
transcriptional and functional activity in primary culture of human
valvular interstitial cells, treated by 5-aza-20-deoxycytidine (AdC)
Previous studies have shown that in myeloid cells the 5-LO pro-
moter is regulated at least in part by levels of DNA methylation in
the promoter region, and that pharmacological inhibition of DNA
methylation leads to increased 5-LO expression. We thus asked
whether a similar regulatory mechanism could be demonstrated
in VICs. Treatment of cultured VICs with the inhibitor of DNA
methylation 5-aza-20-deoxycytidin (AdC; 100 nM–10 lM) signiﬁ-
cantly decreased the relative amount of methylated 5-LO promoter
(0.21 ± 0.18 compared with untreated; p = 0.002; Fig. 2A). This was
accompanied by a 2.47 ± 0.66-fold increase in 5-LO mRNA levels
(p = 0.002; Fig. 2B) and a 1.54 ± 0.24-fold increase in LTB4 produc-
tion (p = 0.025; Fig. 2C).
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Immunoﬂuorescence staining revealed 5-LO protein expression
in VICs derived from human stenotic aortic valves (Fig. 2D). In
these cells, the 5-LO expression exhibited a perinuclear localization
(Fig. 2D).
4. Discussion
Calciﬁed aortic stenosis is associated with increased leukotriene
production, derived from both inﬁltrating leukocytes and an induc-
tion of 5-LO in VICs [12]. The present study points to epigenetic
modiﬁcations as a potential mechanism driving this immune-
transformation of VICs, which is the dominating cell type in aortic
valve tissue.
Calciﬁed human aortic tissue expressed signiﬁcantly higher
levels of 5-LO mRNA compared with non-calciﬁed tissue. These
ﬁndings conﬁrm our previous results [12] and extend the observa-
tion by showing also a signiﬁcantly lower degree of 5-LO promoter
methylation in calciﬁed tissue and hence providing a ﬁrst indica-
tion of epigenetic modulations in valvular calciﬁcation. Interest-
ingly, there was a signiﬁcant and inverse correlation between
5-LO promoter methylation and 5-LO mRNA levels in aortic valves,
supporting the idea that DNA hypomethylation may alter 5-LO
transcription levels in human valvular tissue. Nevertheless,
increased 5-LO expression in a tissue may also in part derive from
higher number of inﬁltrating immune cells, and a deﬁnite causal
relationship between hypomethylation and 5-LO transcription
cannot be established when studying a heterogenous tissue with
several cell types, such as human aortic valves. Therefore, we next
established primary cultures of VICs derived from human aortic
valves.
AdC treatment of VICs signiﬁcantly decreased the degree of
methylation in the CpG-rich region of the 5-LO promoter. This
change was functional, as demonstrated by the signiﬁcant increase
in 5-LO transcription and LTB4 production. Taken together, these
ﬁndings suggest that 5-LO expression can be induced pharmaco-
logically in VICs through epigenetic mechanisms leading to the
production of the proinﬂammatory mediator LTB4. These results
are in line with a previous study showing AdC-induced 5-LO
expression in primary culture of proliferating rat cerebellar granule
neurons [18] and in myeloid cells [8,9], and may provide a possible
explanation for the previously reported expression of 5-LO in VICs
from stenotic aortic valves [12], and in CMV-infected vascular
smooth muscle cells [13]. Here we also demonstrated 5-LO protein
expression in cultured VICs derived from stenotic aortic valves. In
the latter cells, 5-LO exhibited a perinuclear localization, consistent
with the translocation of the 5-LO enzyme to the nuclear envelop
upon cell activation [19].
Taken together, these observations provide a possible mecha-
nistic explanation for phenotypic transformation of VICs into leu-
kotriene-producing immune-like cells in aortic stenosis [12].
Although it should be acknowledged that an indirect effect, such
as the induction of a positive transcriptional regulator of 5-LO
cannot be deﬁnitely ruled out, the inverse correlation of 5-LO pro-
moter methylation and 5-LO transcription points to abnormal DNA
methylation pattern as one possible mechanisms of inducible
genomic instability of activated VICs. The associated leukotriene
production may be one of the functional consequences of pheno-
typic VIC transdifferentiation associated with hemodynamic
progression of aortic valve stenosis. Although not speciﬁcally
explored in the present study, it is interesting that the master tran-
scription factor of osteoblastic differentiation, Runx2, binds to CpG
rich regions in the osteocalcin promoter [20], which could impli-
cate epigenetic mechanisms also in the osteogenic transformationof VICs in aortic stenosis. In support of the latter suggestion,
osteoblasts have been described to express 5-LO [21], and 5-LO
expression correlates with the osteoblastic markers BMP-2 and
BMP-6 in stenotic aortic valves [12].
In summary, the DNA methylation inhibitor AdC altered DNA
methylation status in the CpG islands of the 5-LO promoter in VICs,
with functional consequences for 5-LO transcription and leukotri-
ene production. These in vitro ﬁndings were extended to human
pathology through the demonstration of alterations of methylation
status between calciﬁed and non-calciﬁed human aortic valve tis-
sue. These results indicate that reduced 5-LO promoter hypome-
thylation plays a role in the phenotypic transdifferentiation of
VICs coupled to valvular calciﬁcation, and provide a ﬁrst indication
of epigenetic modiﬁcations in aortic stenosis. To our knowledge,
this is the ﬁrst study providing a conceptual model of phenotypic
plasticity of VICs due to underlying epigenetic alterations, which
may act as functional link between physiological and pathophysi-
ological conditions leading to aortic stenosis development and
progression.
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